摘要
目的观察西洛他唑(CS)对冠心病(CHD)合并2型糖尿病(2DM)患者脂代谢的影响。方法80例CHD合并2-DM患者随机分为2组,A组:普伐他汀20mg每晚1次。B组:普伐他汀20mg每晚1次+西洛他唑50mg,每日2次;另设健康对照组38例,治疗并随访6个月。于入院第2天及治疗3个月后检测血脂水平。结果3个月后A、B2组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)较治疗前降低(P<0.05);B组高密度脂蛋白胆固醇(HDL-C)较治疗前明显升高(P<0.01),TC、LDL-C与A组比较差异无统计学意义(P>0.05),TG显著低于A组,HDL-C显著升高(P<0.01)。B组冠心病加重百分率较A组降低(P<0.05)。结论西洛他唑可降低CHD合并2DM患者的TG水平,并提升HDL-C水平,改善预后。
Objective To study the effect of cilostazol on lipids metabolism in patients with coronary heart disease （CHD） complicated with 2-diabetes mellitus （2-DM）. Methods A total of 80 patients with CHD complicated with 2-DM were divided into two groups randomly. Group A received 20 mg of pravastain every night for 6 months. Group B received 50 mg of cilostazol per 12 hours for 6 months besides of pravastain. Meanwhile, 38 cases of heathly people were as the control group. The serum levels of lipids were determined at second day and 3 months later. Results The serum levels of total cholesterol （TC）, triglyceride （TG） and low density lipoprotein cholesterol （LDL-C） in both groups decreased significantly after 3 months therapy （ P 〈 0. 01 ）. The serum levels of high density lipoprotein cholesterol （HDL-C） of group B raised significantly than before treatment （ P 〈 0.01）. Compared with group A, the levels of TC, LDL-C in group B were no differences （ P 〉 0.05）, and the TG level was lower and the HDL-C was higher significantly （ P 〈0.01）. In addition, the rate of deteriorated CHD was lower than that of group A （ P 〈0.05）. Conclusion Cilostazol can decrease the serum TG level and raise the serum HDL- C level, suggesting it can improve the outcome of patients with coronary heart disease complicated with 2-diabetes mellitus.
出处
《河北医药》
CAS
2008年第10期1473-1475,共3页
Hebei Medical Journal
关键词
冠心病
2型糖尿病
西洛他唑
普伐他汀
总胆固醇
低密度脂蛋白胆固醇
甘油三酯
高密度脂蛋白胆固醇
coronary heart disease （CHD）
2-diabetes mellitus （2DM）
cilostazol （CS）
pravastain
total cholesterol （TC）
low density lipoprotein cholesterol （LDL-C）
triglyceride （TG）
high density lipoprotein cholesterol （HDL-C）
